Home > Boards > US Listed > Medical - Drugs > AstraZeneca PLC (AZN)

AZN buy 40.92

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stocktrademan Member Profile
Followed By 458
Posts 9,981
Boards Moderated 1
Alias Born 04/28/14
160x600 placeholder
AstraZeneca Pledges $1 Billion to Cut CO2 Emissions Dow Jones News - 1/22/2020 5:38:00 AM
Myriad Submits sPMA for BRACAnalysis CDx Test Dow Jones News - 1/21/2020 7:58:00 AM
AstraZeneca, Merck Get FDA Priority Review for Lynparza in Form of Prostate Cancer Dow Jones News - 1/21/2020 7:43:00 AM
Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Metastatic Castration-resistant Prost... GlobeNewswire Inc. - 1/21/2020 7:05:10 AM
AstraZeneca: FDA Gives Orphan Drug Status to Two Liver Cancer Drugs Dow Jones News - 1/20/2020 2:48:00 AM
AstraZeneca's Prostate Cancer Supplemental Drug Gets U.S. Approval Dow Jones News - 1/20/2020 2:46:00 AM
My Green Lab Working with AstraZeneca to Implement Green Labs Program Dow Jones News - 1/14/2020 12:03:00 PM
AstraZeneca Faces $100 Million Impairment After Disappointing Epanova Data -- Update Dow Jones News - 1/13/2020 8:22:00 AM
AstraZeneca, Merck Get FDA Priority Review for Lynparza in Advanced Ovarian Cancer Dow Jones News - 1/13/2020 7:43:00 AM
AstraZeneca to Discontinue Epanova Trial Following Disappointing Data Dow Jones News - 1/13/2020 2:37:00 AM
FDA to Review Extending Uses for AstraZeneca-Controlled Drug Dow Jones News - 1/6/2020 7:51:00 AM
FARXIGA Granted FDA Priority Review For Patients With Heart Failure With Reduced Ejection Fraction Business Wire - 1/6/2020 7:00:00 AM
AstraZeneca, Merck Get FDA OK for Lynparza in Pancreatic Cancer Indication Dow Jones News - 12/30/2019 7:49:00 AM
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germlin... GlobeNewswire Inc. - 12/30/2019 7:05:10 AM
LYNPARZA (Olaparib) Approved in the US as a 1st-line Maintenance Treatment of Germline BRCA-mutated Metastatic Pancreatic Can... Business Wire - 12/30/2019 6:55:00 AM
FDA Approves AstraZeneca's Lynparza for Pancreatic Cancer Dow Jones News - 12/30/2019 2:42:00 AM
ENHERTU (fam-trastuzumab deruxtecan-nxki) Approved in the US for HER2-Positive Unresectable or Metastatic Breast Cancer Follo... Business Wire - 12/20/2019 6:04:00 PM
AstraZeneca Sells Rights to Two Cancer Medicines for $181 Million Up Front Dow Jones News - 12/20/2019 2:41:00 AM
AstraZeneca, Merck Say FDA Panel Recommends Lynparza in Pancreatic Cancer Dow Jones News - 12/17/2019 3:05:00 PM
AstraZeneca: Imfinzi Approved in China for Stage III Nonsmall-Cell Lung Cancer Dow Jones News - 12/12/2019 2:53:00 AM
[Fam]-Trastuzumab Deruxtecan Achieved a Tumor Response of 60.9% in Pivotal Phase II HER2-positive Metastatic Breast Cancer Tr... Business Wire - 12/11/2019 8:00:00 AM
CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chroni... Business Wire - 12/7/2019 7:50:00 AM
AstraZeneca Sells Seroquel Rights to Cheplapharm Dow Jones News - 12/3/2019 2:47:00 AM
AstraZeneca Gets US License for Imfinzi Lung-Cancer Drug Dow Jones News - 11/29/2019 2:43:00 AM
CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia Business Wire - 11/21/2019 2:54:00 PM
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist